AstraZeneca (AZN)
NASDAQ: AZN
· Real-Time Price · USD
79.17
0.70 (0.89%)
At close: Aug 15, 2025, 3:42 PM
AstraZeneca Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 3.13B | 2.92B | 1.67B | 1.83B | 2.4B | 2.8B | 897M | 1.65B | 2.09B | 2.26B | 778M | 923M | 247M | 553M | -636M | -2B | 764M | 1.61B |
Depreciation & Amortization | 1.39B | 1.28B | 714M | 1.82B | 1.28B | 1.25B | 874M | 1.28B | 1.28B | 1.5B | 1.48B | 1.33B | 1.36B | 1.31B | 2.19B | 2.79B | 753M | 797M |
Stock-Based Compensation | n/a | n/a | n/a | n/a | n/a | n/a | 579M | n/a | n/a | n/a | 619M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | -345M | -426M | -350M | 41M | -129M | -455M | -150M | 897M | -989M | 242M | -2.29B | 1.07B | 587M | 1.8B | -2.06B | 1.21B | -353M | 1.21B |
Other Non-Cash Items | -785M | -61M | 877M | -303M | -462M | -1.11B | 459M | -717M | -657M | -873M | -159M | -394M | -943M | -434M | 1.31B | -274M | -272M | -1.68B |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -579M | n/a | n/a | n/a | -619M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -345M | -426M | -350M | 41M | -129M | -455M | 150M | 897M | -989M | 242M | 299M | 1.07B | 587M | 1.8B | -1.45B | 1.21B | -353M | 1.21B |
Operating Cash Flow | 3.39B | 3.71B | 2.91B | 3.38B | 3.08B | 2.49B | 2.38B | 3.11B | 1.72B | 3.13B | 2.4B | 2.93B | 1.25B | 3.23B | 1.42B | 1.72B | 892M | 1.93B |
Capital Expenditures | -1.92B | -429M | -955M | -1.36B | -668M | -1.6B | -946M | -879M | -483M | -1.47B | -554M | -1.11B | -543M | -363M | -718M | -660M | -353M | -469M |
Cash Acquisitions | -267M | -362M | -274M | -281M | -2.3B | -940M | -296M | -273M | -184M | -426M | -189M | -342M | -288M | -242M | -218M | -9.63B | -138M | 550M |
Purchase of Investments | -188M | n/a | n/a | -29M | 31M | n/a | -15M | -95M | -26M | n/a | 190M | -321M | -24M | -4M | 6M | -180M | -10M | 249M |
Sales Maturities Of Investments | 114M | n/a | -32M | 47M | 84M | 9M | 97M | -68M | 81M | 19M | n/a | -2M | -9M | 53M | -15M | -15M | 107M | 28M |
Other Investing Acitivies | -1.11B | -462M | -167M | -834M | -308M | 123M | 83M | 94M | 92M | 631M | 304M | 33M | 64M | 388M | 32M | 18M | 158M | 197M |
Investing Cash Flow | -2.11B | -1.25B | -1.18B | -1.51B | -2.87B | -2.41B | -1.08B | -1.22B | -520M | -1.25B | -249M | -1.74B | -800M | -168M | -913M | -10.46B | -236M | 555M |
Debt Repayment | 632M | 1.09B | -608M | -2.42B | -1.13B | 5.97B | -236M | -1.21B | -1.44B | 1.92B | -72M | 58M | -1.24B | -78M | -853M | 1.6B | -668M | -54M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | -10M | -3.35B | -3M | -1.58B | -17M | -3.03B | -2M | -1.41B | -22M | -3.05B | n/a | -1.39B | n/a | -2.97B | n/a | -1.39B | n/a | -2.47B |
Other Financial Acitivies | -105M | 23M | -83M | -59M | -76M | -915M | -74M | -111M | -62M | -907M | -304M | -98M | -60M | -696M | -217M | -68M | 7.96B | -213M |
Financial Cash Flow | 518M | -2.71B | -671M | -4.13B | -1.22B | 2.03B | -291M | -2.73B | -1.52B | -2.03B | -358M | -1.43B | -1.29B | -3.74B | -1.05B | 142M | 7.29B | -2.73B |
Net Cash Flow | 1.82B | -222M | 994M | -2.24B | -1.01B | 2.06B | 1.02B | -852M | -357M | -155M | 1.8B | -294M | -873M | -685M | -535M | -8.62B | 7.96B | -309M |
Free Cash Flow | 1.46B | 3.28B | 1.95B | 2.02B | 2.42B | 881M | 1.43B | 2.23B | 1.24B | 1.66B | 1.84B | 1.82B | 705M | 2.87B | 700M | 1.06B | 539M | 1.47B |